Jason Bradley Terrell MD - 23 Jun 2022 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role
Chief Medical Officer
Signature
/s/ Jason Bradley Terrell MD
Issuer symbol
VNRX
Transactions as of
23 Jun 2022
Net transactions value
$0
Form type
4
Filing time
24 Jun 2022, 16:02:07 UTC
Previous filing
07 Jun 2022
Next filing
05 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNRX Common Stock Award $0 +22,845 +186% $0.000000 35,145 23 Jun 2022 Direct F1
transaction VNRX Common Stock Award $0 +1,775 +186% $0.000000 2,730 23 Jun 2022 By Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNRX Stock Option (Right to Buy) Award $0 +42,098 +186% $0.000000 64,766 23 Jun 2022 Common Stock 42,098 $3.40 Direct F3
transaction VNRX Stock Option (Right to Buy) Award $0 +3,270 +186% $0.000000 5,030 23 Jun 2022 Common Stock 3,270 $3.40 By Spouse F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 22,845 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 11,423 units and 11,422 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 12,300 restricted stock units subject to the award previously vested and remain subject to time-based vesting.
F2 On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 1,775 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 888 units and 887 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 955 restricted stock units subject to the award previously vested and remain subject to time-based vesting.
F3 On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,098 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 21,049 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 22,668 shares subject to the award previously vested and remain subject to time-based vesting.
F4 On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,270 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,635 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 1,760 shares subject to the award previously vested and remain subject to time-based vesting.